Merus NV ((MRUS)) announced an update on their ongoing clinical study.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Merus N.V. recently updated its Phase 2 clinical study evaluating zenocutuzumab (MCLA-128) in patients with specific cancer types. Officially titled ‘A Phase 2 Study Evaluating Activity of Zenocutuzumab (MCLA-128) in Patients With or Without Molecularly Defined Cancers,’ the study aims to assess the efficacy of zenocutuzumab in treating NSCLC with NRG1 fusion and metastatic castration-resistant prostate cancer (mCRPC). This study is significant as it explores targeted treatments for these challenging cancer types.
The study tests zenocutuzumab, a bispecific antibody targeting HER2 and HER3, in combination with other drugs like afatinib, enzalutamide, or abiraterone, depending on the cancer type. These interventions aim to improve treatment outcomes by targeting specific cancer pathways.
Designed as an interventional, non-randomized, open-label study with a parallel assignment model, the primary purpose is treatment. The study does not use masking, allowing for direct observation of treatment effects.
The study began on October 14, 2022, but was terminated as of the last update on September 12, 2025. The termination of the study is crucial for investors as it may influence Merus N.V.’s stock performance and investor sentiment, especially in the competitive oncology market.
The termination of this study could impact Merus N.V.’s position in the market, potentially affecting investor confidence. Competitors in the oncology sector may gain an advantage as Merus reassesses its strategy.
The study has been terminated, and further details can be found on the ClinicalTrials portal.